Eintrag weiter verarbeiten
P14.82 Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: a retrospective study
Gespeichert in:
| Zeitschriftentitel: | Neuro-Oncology |
|---|---|
| Personen und Körperschaften: | |
| In: | Neuro-Oncology, 21, 2019, Supplement_3, S. iii87-iii87 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Oxford University Press (OUP)
|
| Schlagwörter: |
| author_facet |
Zhang, J Zhang, J |
|---|---|
| author |
Zhang, J |
| spellingShingle |
Zhang, J Neuro-Oncology P14.82 Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: a retrospective study Cancer Research Neurology (clinical) Oncology |
| author_sort |
zhang, j |
| spelling |
Zhang, J 1522-8517 1523-5866 Oxford University Press (OUP) Cancer Research Neurology (clinical) Oncology http://dx.doi.org/10.1093/neuonc/noz126.317 <jats:title>Abstract</jats:title> <jats:sec> <jats:title>BACKGROUND</jats:title> <jats:p>The optimal chemotherapeutics of recurrent disseminated glioblastoma has yet to be determined. We analyzed the efficacy and safety of temozolomide (TMZ) and irinotecan (CPT-11) combined with recombinant human endostatin (rh-ES) in patients with recurrent disseminated glioblastoma.</jats:p> </jats:sec> <jats:sec> <jats:title>MATERIAL AND METHODS</jats:title> <jats:p>We retrospectively reviewed 30 adult patients with recurrent disseminated glioblastoma treated with this combination chemotherapy from November 2009 to August 2018. TMZ was given orally 200mg/m2 for 5 days in each 28-day cycle (5/28d). CPT-11 was administrated 125 mg/m2 for patients not receiving enzyme-inducing antiepileptic drugs (EIAEDs) or 340 mg/m2 for patients receiving EIAEDs on day 1 and day 15; rh-ES was administrated 15 mg/d, daily for 14 days of each 28-day treatment cycle.</jats:p> </jats:sec> <jats:sec> <jats:title>RESULTS</jats:title> <jats:p>Primary endpoint was progression-free survival at 6 months (6m-PFS). The 6m-PFS was 23.3%. The median PFS was 3.2 months. The overall survival rate (OS) at 12 months was 28.6%. The median OS was 6.9 months. Six out of 30 (20%) patients demonstrated partial radiographic response and 11/30 (36.7%) remained stable. The PFS of the 6 patients who got partial response was 5.8, 6.3, 6.9, 13.6, 15.8, 16.6 months, respectively, and the median time interval of first response was 4 (range, 2.0–6.6) months. The most common adverse events were hematologic toxicity and gastrointestinal reactions. The Grade ≥3 adverse event was mainly hematologic toxicity. The adverse events were manageable.</jats:p> </jats:sec> <jats:sec> <jats:title>CONCLUSION</jats:title> <jats:p>Rh-ES, in combination with cytotoxic drugs, was an alternative effective regimen with manageable toxicity in treatment of recurrent disseminated glioblastoma.</jats:p> </jats:sec> P14.82 Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: a retrospective study Neuro-Oncology |
| doi_str_mv |
10.1093/neuonc/noz126.317 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5My9uZXVvbmMvbm96MTI2LjMxNw |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5My9uZXVvbmMvbm96MTI2LjMxNw |
| institution |
DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 |
| imprint |
Oxford University Press (OUP), 2019 |
| imprint_str_mv |
Oxford University Press (OUP), 2019 |
| issn |
1522-8517 1523-5866 |
| issn_str_mv |
1522-8517 1523-5866 |
| language |
English |
| mega_collection |
Oxford University Press (OUP) (CrossRef) |
| match_str |
zhang2019p1482combiningtherapywithrecombinanthumanendostatinandcytotoxicagentsforrecurrentdisseminatedglioblastomaaretrospectivestudy |
| publishDateSort |
2019 |
| publisher |
Oxford University Press (OUP) |
| recordtype |
ai |
| record_format |
ai |
| series |
Neuro-Oncology |
| source_id |
49 |
| title |
P14.82 Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: a retrospective study |
| title_unstemmed |
P14.82 Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: a retrospective study |
| title_full |
P14.82 Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: a retrospective study |
| title_fullStr |
P14.82 Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: a retrospective study |
| title_full_unstemmed |
P14.82 Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: a retrospective study |
| title_short |
P14.82 Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: a retrospective study |
| title_sort |
p14.82 combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: a retrospective study |
| topic |
Cancer Research Neurology (clinical) Oncology |
| url |
http://dx.doi.org/10.1093/neuonc/noz126.317 |
| publishDate |
2019 |
| physical |
iii87-iii87 |
| description |
<jats:title>Abstract</jats:title>
<jats:sec>
<jats:title>BACKGROUND</jats:title>
<jats:p>The optimal chemotherapeutics of recurrent disseminated glioblastoma has yet to be determined. We analyzed the efficacy and safety of temozolomide (TMZ) and irinotecan (CPT-11) combined with recombinant human endostatin (rh-ES) in patients with recurrent disseminated glioblastoma.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>MATERIAL AND METHODS</jats:title>
<jats:p>We retrospectively reviewed 30 adult patients with recurrent disseminated glioblastoma treated with this combination chemotherapy from November 2009 to August 2018. TMZ was given orally 200mg/m2 for 5 days in each 28-day cycle (5/28d). CPT-11 was administrated 125 mg/m2 for patients not receiving enzyme-inducing antiepileptic drugs (EIAEDs) or 340 mg/m2 for patients receiving EIAEDs on day 1 and day 15; rh-ES was administrated 15 mg/d, daily for 14 days of each 28-day treatment cycle.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>RESULTS</jats:title>
<jats:p>Primary endpoint was progression-free survival at 6 months (6m-PFS). The 6m-PFS was 23.3%. The median PFS was 3.2 months. The overall survival rate (OS) at 12 months was 28.6%. The median OS was 6.9 months. Six out of 30 (20%) patients demonstrated partial radiographic response and 11/30 (36.7%) remained stable. The PFS of the 6 patients who got partial response was 5.8, 6.3, 6.9, 13.6, 15.8, 16.6 months, respectively, and the median time interval of first response was 4 (range, 2.0–6.6) months. The most common adverse events were hematologic toxicity and gastrointestinal reactions. The Grade ≥3 adverse event was mainly hematologic toxicity. The adverse events were manageable.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>CONCLUSION</jats:title>
<jats:p>Rh-ES, in combination with cytotoxic drugs, was an alternative effective regimen with manageable toxicity in treatment of recurrent disseminated glioblastoma.</jats:p>
</jats:sec> |
| container_issue |
Supplement_3 |
| container_start_page |
0 |
| container_title |
Neuro-Oncology |
| container_volume |
21 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792323336676573187 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T11:30:04.872Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=P14.82+Combining+therapy+with+recombinant+human+endostatin+and+cytotoxic+agents+for+recurrent+disseminated+glioblastoma%3A+a+retrospective+study&rft.date=2019-09-06&genre=article&issn=1523-5866&volume=21&issue=Supplement_3&pages=iii87-iii87&jtitle=Neuro-Oncology&atitle=P14.82+Combining+therapy+with+recombinant+human+endostatin+and+cytotoxic+agents+for+recurrent+disseminated+glioblastoma%3A+a+retrospective+study&aulast=Zhang&aufirst=J&rft_id=info%3Adoi%2F10.1093%2Fneuonc%2Fnoz126.317&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792323336676573187 |
| author | Zhang, J |
| author_facet | Zhang, J, Zhang, J |
| author_sort | zhang, j |
| container_issue | Supplement_3 |
| container_start_page | 0 |
| container_title | Neuro-Oncology |
| container_volume | 21 |
| description | <jats:title>Abstract</jats:title> <jats:sec> <jats:title>BACKGROUND</jats:title> <jats:p>The optimal chemotherapeutics of recurrent disseminated glioblastoma has yet to be determined. We analyzed the efficacy and safety of temozolomide (TMZ) and irinotecan (CPT-11) combined with recombinant human endostatin (rh-ES) in patients with recurrent disseminated glioblastoma.</jats:p> </jats:sec> <jats:sec> <jats:title>MATERIAL AND METHODS</jats:title> <jats:p>We retrospectively reviewed 30 adult patients with recurrent disseminated glioblastoma treated with this combination chemotherapy from November 2009 to August 2018. TMZ was given orally 200mg/m2 for 5 days in each 28-day cycle (5/28d). CPT-11 was administrated 125 mg/m2 for patients not receiving enzyme-inducing antiepileptic drugs (EIAEDs) or 340 mg/m2 for patients receiving EIAEDs on day 1 and day 15; rh-ES was administrated 15 mg/d, daily for 14 days of each 28-day treatment cycle.</jats:p> </jats:sec> <jats:sec> <jats:title>RESULTS</jats:title> <jats:p>Primary endpoint was progression-free survival at 6 months (6m-PFS). The 6m-PFS was 23.3%. The median PFS was 3.2 months. The overall survival rate (OS) at 12 months was 28.6%. The median OS was 6.9 months. Six out of 30 (20%) patients demonstrated partial radiographic response and 11/30 (36.7%) remained stable. The PFS of the 6 patients who got partial response was 5.8, 6.3, 6.9, 13.6, 15.8, 16.6 months, respectively, and the median time interval of first response was 4 (range, 2.0–6.6) months. The most common adverse events were hematologic toxicity and gastrointestinal reactions. The Grade ≥3 adverse event was mainly hematologic toxicity. The adverse events were manageable.</jats:p> </jats:sec> <jats:sec> <jats:title>CONCLUSION</jats:title> <jats:p>Rh-ES, in combination with cytotoxic drugs, was an alternative effective regimen with manageable toxicity in treatment of recurrent disseminated glioblastoma.</jats:p> </jats:sec> |
| doi_str_mv | 10.1093/neuonc/noz126.317 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5My9uZXVvbmMvbm96MTI2LjMxNw |
| imprint | Oxford University Press (OUP), 2019 |
| imprint_str_mv | Oxford University Press (OUP), 2019 |
| institution | DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161 |
| issn | 1522-8517, 1523-5866 |
| issn_str_mv | 1522-8517, 1523-5866 |
| language | English |
| last_indexed | 2024-03-01T11:30:04.872Z |
| match_str | zhang2019p1482combiningtherapywithrecombinanthumanendostatinandcytotoxicagentsforrecurrentdisseminatedglioblastomaaretrospectivestudy |
| mega_collection | Oxford University Press (OUP) (CrossRef) |
| physical | iii87-iii87 |
| publishDate | 2019 |
| publishDateSort | 2019 |
| publisher | Oxford University Press (OUP) |
| record_format | ai |
| recordtype | ai |
| series | Neuro-Oncology |
| source_id | 49 |
| spelling | Zhang, J 1522-8517 1523-5866 Oxford University Press (OUP) Cancer Research Neurology (clinical) Oncology http://dx.doi.org/10.1093/neuonc/noz126.317 <jats:title>Abstract</jats:title> <jats:sec> <jats:title>BACKGROUND</jats:title> <jats:p>The optimal chemotherapeutics of recurrent disseminated glioblastoma has yet to be determined. We analyzed the efficacy and safety of temozolomide (TMZ) and irinotecan (CPT-11) combined with recombinant human endostatin (rh-ES) in patients with recurrent disseminated glioblastoma.</jats:p> </jats:sec> <jats:sec> <jats:title>MATERIAL AND METHODS</jats:title> <jats:p>We retrospectively reviewed 30 adult patients with recurrent disseminated glioblastoma treated with this combination chemotherapy from November 2009 to August 2018. TMZ was given orally 200mg/m2 for 5 days in each 28-day cycle (5/28d). CPT-11 was administrated 125 mg/m2 for patients not receiving enzyme-inducing antiepileptic drugs (EIAEDs) or 340 mg/m2 for patients receiving EIAEDs on day 1 and day 15; rh-ES was administrated 15 mg/d, daily for 14 days of each 28-day treatment cycle.</jats:p> </jats:sec> <jats:sec> <jats:title>RESULTS</jats:title> <jats:p>Primary endpoint was progression-free survival at 6 months (6m-PFS). The 6m-PFS was 23.3%. The median PFS was 3.2 months. The overall survival rate (OS) at 12 months was 28.6%. The median OS was 6.9 months. Six out of 30 (20%) patients demonstrated partial radiographic response and 11/30 (36.7%) remained stable. The PFS of the 6 patients who got partial response was 5.8, 6.3, 6.9, 13.6, 15.8, 16.6 months, respectively, and the median time interval of first response was 4 (range, 2.0–6.6) months. The most common adverse events were hematologic toxicity and gastrointestinal reactions. The Grade ≥3 adverse event was mainly hematologic toxicity. The adverse events were manageable.</jats:p> </jats:sec> <jats:sec> <jats:title>CONCLUSION</jats:title> <jats:p>Rh-ES, in combination with cytotoxic drugs, was an alternative effective regimen with manageable toxicity in treatment of recurrent disseminated glioblastoma.</jats:p> </jats:sec> P14.82 Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: a retrospective study Neuro-Oncology |
| spellingShingle | Zhang, J, Neuro-Oncology, P14.82 Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: a retrospective study, Cancer Research, Neurology (clinical), Oncology |
| title | P14.82 Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: a retrospective study |
| title_full | P14.82 Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: a retrospective study |
| title_fullStr | P14.82 Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: a retrospective study |
| title_full_unstemmed | P14.82 Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: a retrospective study |
| title_short | P14.82 Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: a retrospective study |
| title_sort | p14.82 combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: a retrospective study |
| title_unstemmed | P14.82 Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: a retrospective study |
| topic | Cancer Research, Neurology (clinical), Oncology |
| url | http://dx.doi.org/10.1093/neuonc/noz126.317 |